Moreover, treatment with a SCD1-specific antagonist in patients with NAFLD decreased hepatic lipogenesis, but did not improve hyperglycemia or insulin resistance48. This evidence concerns the gene SCD and metabolic dysfunction-associated steatotic liver disease.